PF 6305591

Drug Profile

PF 6305591

Alternative Names: PF-06305591; PF-6305591

Latest Information Update: 11 Mar 2014

Price : $50

At a glance

  • Originator Pfizer
  • Class Analgesics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 28 Feb 2014 Discontinued - Phase-I for Pain in Belgium (PO, liquid)
  • 28 Feb 2014 Discontinued - Phase-I for Pain in Belgium (PO, tablet)
  • 30 Nov 2013 Pfizer completes a phase I trial in healthy volunteers in Belgium (NCT01776619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top